» Articles » PMID: 24702857

Search for Novel Histone Deacetylase Inhibitors. Part II: Design and Synthesis of Novel Isoferulic Acid Derivatives

Overview
Journal Bioorg Med Chem
Specialties Biochemistry
Chemistry
Date 2014 Apr 8
PMID 24702857
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we described the discovery of potent ferulic acid-based histone deacetylase inhibitors (HDACIs) with halogeno-acetanilide as novel surface recognition moiety (SRM). In order to improve the affinity and activity of these HDACIs, twenty seven isoferulic acid derivatives were described herein. The majority of title compounds displayed potent HDAC inhibitory activity. In particular, IF5 and IF6 exhibited significant enzymatic inhibitory activities, with IC50 values of 0.73 ± 0.08 and 0.57 ± 0.16 μM, respectively. Furthermore, these compounds showed moderate antiproliferative activity against human cancer cells. Especially, IF6 displayed promising profile as an antitumor candidate with IC50 value of 3.91 ± 0.97 μM against HeLa cells. The results indicated that these isoferulic acid derivatives could serve as promising lead compounds for further optimization.

Citing Articles

Exploration of Structure-Activity Relationship Using Integrated Structure and Ligand Based Approach: Hydroxamic Acid-Based HDAC Inhibitors and Cytotoxic Agents.

Shirbhate E, Pandey J, Patel V, Veerasamy R, Rajak H Turk J Pharm Sci. 2023; 20(4):270-284.

PMID: 37606012 PMC: 10445225. DOI: 10.4274/tjps.galenos.2022.12269.


Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.

Mourad A, Mourad M, Jones P Drug Des Devel Ther. 2020; 14:3111-3130.

PMID: 32848361 PMC: 7425103. DOI: 10.2147/DDDT.S256756.


Isoferulic acid inhibits human leukemia cell growth through induction of G2/M‑phase arrest and inhibition of Akt/mTOR signaling.

Long Z, Feng G, Zhao N, Wu L, Zhu H Mol Med Rep. 2020; 21(3):1035-1042.

PMID: 31922221 PMC: 7002969. DOI: 10.3892/mmr.2020.10926.